Bronchodilator response in COPD: absent or wrong method of measurement?

Can a novel measure of acute bronchodilator responsiveness predict improvement in exercise capacity after four weeks treatment with tiotropium bromide in subjects with chronic obstructive pulmonary disease?

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000304639

Enrollment

Registered

2005-09-06

Start date

2004-01-05

Completion date

2005-01-05

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Salbutamol (200mcg), by metered dose inhaler, plus tiotropium bromide (18mcg), by dry powder inhaler, on one occasion, or placebo metered dose inhaler plus placebo capsule, by dry powder inhaler, on one occasion Tiotropium bromide, 18mcg/day for four weeks, open label.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Diagnosis

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Moderate to severe chronic obstructive pulmonary disease, with FEV1 < 60% predicted and FEV1/FVC<70%

Exclusion criteria

No exclusion criteria

Outcome results